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OBJECTIVES We sought to test whether one month of daily oral conjugated equine estrogen (CEE) or
transdermal estradiol alters hemostatic factors in postmenopausal subjects.
BACKGROUND Estrogen replacement therapy and hormonal replacement therapy (HRT) effect an early
increase in cardiovascular events in postmenopausal women. Circulating plasma von Wille-
brand factor (vWF) antigen is a marker of generalized endothelial dysfunction and
atherothrombosis.
METHODS Thirty-eight healthy postmenopausal women (average 59  7 years) were randomized to
receive daily oral CEE, 0.625 mg (n 21); transdermal estradiol, 0.1 mg/day (n 7); or oral
placebo (n 10) for one month. Blood samples were collected at baseline and after two weeks
and four weeks of therapy for measurement of circulating plasma hormones, lipid concen-
trations, and hemostatic factors.
RESULTS Oral CEE decreased total cholesterol (p 0.01) and low-density lipoprotein cholesterol (p
0.01), although it increased both triglycerides (p  0.05) and high-density lipoprotein
cholesterol (p  0.01). Transdermal estradiol had no significant effect on lipids. Plasminogen
activator inhibitor-1 antigen declined in both oral CEE and transdermal estradiol users, but
did not achieve statistical significance. Fibrin D-dimer antigen did not vary significantly in any
group. However, oral CEE users had a significant increase in vWF from baseline to four
weeks (p  0.03) and a decrease in tissue-type plasminogen activator antigen from baseline
to four weeks (p  0.004), which was significantly different from the change observed in the
transdermal estradiol group (p  0.05).
CONCLUSIONS These data suggest that the oral CEE-mediated increase in plasma vWF may have clinical
relevance given the early atherothrombotic effects of HRT in postmenopausal
women. (J Am Coll Cardiol 2002;40:1991–9) © 2002 by the American College of
Cardiology Foundation
Cardiovascular disease is the leading cause of mortality for
women in the U.S. (1,2). The role of hormone replacement
therapy (HRT) with estrogen and progesterone for primary
and secondary prevention of coronary artery disease in
women remains controversial. Observational studies have
demonstrated that women who had used estrogen-
replacement therapy (ERT) with or without progestins (i.e.,
HRT) during the menopausal years had a lower incidence of
cardiovascular events, as compared with untreated women
(3,4). Indeed, several potential mechanisms attributed to
ERT or HRT had been considered to account for a
beneficial effect. For example, oral exogenous estrogen
increases the level of high-density lipoprotein (HDL) cho-
lesterol and decreases the concentration of low-density
lipoprotein (LDL). Moreover, several studies have sug-
gested that ERT or HRT exerts a profibrinolytic effect by
reducing plasminogen activator inhibitor-1 (PAI-1), the
endogenous inhibitor of tissue-type plasminogen activator
(t-PA) and urokinase plasminogen activator (5–15).
However, recent studies have cast doubt on the cardio-
protective effects of HRT. The secondary prevention trial—
the Heart and Estrogen/progestin Replacement Study
(HERS)—examined 2,763 subjects with proven coronary
artery disease and randomized them to conjugated equine-
estrogen (CEE) with medroxyprogesterone acetate (MPA)
or placebo (16). Over a four-year period, there was no
difference in the number of secondary cardiovascular events
and adverse events from peripheral vascular disease between
the HRT-treated subjects and the placebo-treated subjects
(16). The group receiving HRT experienced a 50% higher
cardiac event rate during the first year (absolute excess of
1.4%) and a lower rate from the third year onward. The
investigators considered that the results might be attribut-
able to dual effects, such as an immediate prothrombotic,
proarrhythmic, or proischemic effect that was later out-
weighed by slower progression of atherosclerosis. In further
support of the lack of a benefit from HERS, the Estrogen
Replacement and Atherosclerosis (ERA) trial demonstrated
that three years of treatment with either CEE or CEE with
MPA did not slow the rate of angiographic coronary artery
disease progression, compared with placebo, in 309 post-
menopausal women with established coronary artery disease
(17).
The von Willebrand factor (vWF) has recently been
proposed as a marker of generalized endothelial dysfunc-
tion, and as such, may contribute to the development of
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atherothrombotic disease (18,19). vWF is synthesized by
the endothelium and megakaryocytes, and increased con-
centrations of vWF have been found in patients with
peripheral vascular disease, cerebral vascular disease, and
coronary artery disease (20–22). In addition, patients with
known disease are at greater risk of cardiovascular mortality
if they have high concentrations of vWF (21–25). The
Hoorn study of 631 patients demonstrated that increased
vWF is independently associated with cardiovascular and
all-cause mortality in both diabetic and nondiabetic patients
(26).
We hypothesized that the early effects of treatment with
oral CEE in postmenopausal women might increase mark-
ers associated with endothelial dysfunction, such as vWF.
Therefore, we conducted a short-term study and measured
the concentrations of vWF, lipids, and other hemostatic
factors in postmenopausal subjects receiving daily oral CEE
versus transdermal estradiol or placebo for one month. In
this study, we demonstrate that one-month treatment with
oral CEE, but not transdermal estradiol, significantly in-
creases vWF, thereby potentially increasing the likelihood
of cardiovascular events.
METHODS
The Institutional Review Board of the Columbia–
Presbyterian Medical Center approved the protocol, and
written, informed consent was obtained from each subject,
in accordance with institutional guidelines. Subjects who
were postmenopausal for at least one year participated.
Menopausal status was confirmed by measures of the
estradiol concentration (50 pg/ml) and follicle-
stimulating hormone (20 mU/ml), consistent with meno-
pause. No subject was currently taking or had previously
taken ERT within the past year. Exclusion criteria included
a personal or immediate family history of breast or endo-
metrial cancer, previous myocardial infarction, coronary
artery disease, thrombophlebitis or a history of thromboem-
bolic disease, and a previous adverse reaction to estrogen.
Only subjects with a normal mammogram within the year
were enrolled. Subjects with an abnormal metabolic-renal
profile, including hyperglycemia and hypercalcemia, were
not enrolled.
Subjects underwent testing at baseline and after two and
four weeks of therapy. At enrollment, each had a history and
physical examination. Venous blood samples were collected
during each visit. At baseline and after four weeks, blood
was collected for a complete blood count, chemical-
metabolic profile—including electrolytes, hepatic and renal
function, total cholesterol, LDL cholesterol, HDL choles-
terol, triglycerides, estradiol, follicle-stimulating hormone,
progesterone, luteinizing hormone—and urinalysis, as well
as t-PA antigen, PAI-1 antigen, fibrin D-dimer, vWF
antigen, and fibrinogen. After two weeks, blood was also
collected for hormonal and hemostatic factors to assess
patient compliance.
Subjects were entered into a randomized, double-blind,
placebo-controlled trial using one of two forms of hormonal
replacement: oral CEE (Premarin), 0.625 mg/day, or trans-
dermal estrogen (Climara), 0.1 mg/day. Because concurrent
progestins given in conjunction with CEE may offset
estrogenic effects, we elected to treat subjects with estrogen
monotherapy. Subjects were randomized by means of a
random table to three groups in a ratio of 2:1:1, as to
whether they received oral CEE, transdermal estrogen, or
oral placebo, respectively. The rationale for the randomiza-
tion scheme, which favored oral administration, was the
consideration that the majority of women prescribed post-
menopausal ERT use CEE.
There were 55 subjects enrolled: 48 were randomized,
and 38 completed the trial. Three subjects randomized to
oral CEE did not complete the study because of stomach
upset (n  1) or noncompliance (n  2). Three subjects
randomized to transdermal estrogen did not complete the
study because of vaginal bleeding (n  1), noncompliance
(n  1), and elective withdrawal (n  1). Four randomized
to placebo did not complete the study because of migraine
headache (n  1), noncompliance (n  1), a hormone
concentration that did not meet entry criteria for menopause
(n  1), and generalized discomfort following medication
(n  1). Thirty-eight postmenopausal subjects completed
the study. The subjects (average age 59  7 years) received
daily oral CEE, 0.625 mg (n  21); transdermal estradiol,
0.1 mg/day (n 7); or oral placebo (n 10) for one month.
Plasma samples were collected before and after treatment
in the morning, at the same time of the day for each visit.
Blood samples were drawn at rest from a large antecubital
vein into 0.1 mol/liter trisodium citrate tubes for analysis of
t-PA antigen, PAI-1 antigen, fibrin D-dimer antigen, and
vWF. The tubes were immediately centrifuged and spun at
3,000g for 20 min at 4°C. This centrifugation was per-
formed within 1 h. The plasma was removed into aliquots
and stored at 80°C for up to four months before analysis.
The assays for PAI-1, t-PA, and vWF were determined
using the respective enzyme-linked immunosorbent assay
(ELISA) kits purchased from American Diagnostics, Inc.
(Greenwich, Connecticut). The t-PA antigen measured by
ELISA was the total amount of t-PA present (free and
complexed t-PA, single-chain and double-chain t-PA) (27).
The PAI-1 antigen measured by ELISA was the total
Abbreviations and Acronyms
CEE  conjugated equine estrogen
CRP  C-reactive protein
ERT  estrogen replacement therapy
HDL  high-density lipoprotein cholesterol
HRT  hormone replacement therapy
LDL  low-density lipoprotein cholesterol
MPA  medroxyprogesterone acetate
PAI-1  plasminogen activator inhibitor-1
t-PA  tissue-type plasminogen activator
vWF  von Willebrand factor
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quantity of PAI-1 present (free or complexed with t-PA;
active or inactive form) (27). Fibrin D-dimer was analyzed
using the Asserachrom D-Di ELISA from Diagnostica
Stago (Asnieres-Sur-Seine, France). Estradiol, progester-
one, follicle-stimulating hormone, and luteinizing hormone
concentrations were determined by their specific immuno-
assays from Diagnostic Products Corp. (Los Angeles, Cal-
ifornia), according to the manufacturer’s instructions. Inter-
assay coefficient of variation for estradiol at high, middle,
and low control concentrations are 3.5%, 4.6%, and 9.6%,
respectively. Total cholesterol, LDL cholesterol, HDL cho-
lesterol, triglyceride, and fibrinogen concentrations were
determined by conventional enzymatic methods.
Statistical analysis. Data on baseline characteristics were
analyzed by ANOVA, with post-hoc differences in mean
values among groups assessed using Tukey’s procedure.
Statistical significance was defined as a two-sided p value
0.05. The effect of estrogen within each group on hor-
mones and lipid concentrations was determined using a
two-tailed, paired Student t test. In addition, to correct for
individual differences in baseline values among subjects,
relative changes in the effect of estrogen treatment within
each group on hormones, lipids, and hemostatic factor
concentrations were assessed using a log-transform of the
various factors.
RESULTS
Table 1 shows the baseline characteristics of the assigned
subjects. There were no significant differences among the
placebo, oral CEE, and transdermal estradiol groups at
baseline.
Table 2 shows the effect of oral CEE and transdermal
estradiol therapy on hormones and lipids after one month.
Subjects assigned to oral CEE experienced a significant
increase in estradiol (p  0.01) and a decrease in follicle-
stimulating hormone from baseline to four weeks (p 
0.01). Transdermal estradiol users experienced a nonsignif-
icant increase in estradiol (p  NS) and a significant
decrease in follicle-stimulating hormone at four weeks (p 
0.01). Subjects assigned to oral CEE experienced a signif-
icant decrease in total cholesterol (p  0.01) and LDL
cholesterol (p  0.01) and an increase in triglycerides (p 
0.05) and HDL cholesterol (p 0.01). Neither transdermal
estradiol nor placebo had a significant effect on lipids.
Table 3 and Figure 1 show the effect of oral CEE and
transdermal estradiol on hemostatic factors; there was no
effect of placebo on hemostatic factors. For the subjects
randomized to oral CEE and transdermal estradiol, PAI-1
(ng/ml) declined, but it achieved only borderline signifi-
cance (p  0.08), and only in the oral CEE subjects. There
was a significant decrease in t-PA antigen (p  0.004) after
oral CEE. Fibrin D-dimer did not vary significantly in any
group. However, oral CEE users experienced a significant
increase (p  0.03) in vWF from baseline to four weeks,
which was significantly different from the change observed
in the transdermal estradiol group. Neither oral CEE nor
transdermal estradiol had significant effects on fibrinogen.
The change observed for t-PA in the oral CEE group was
significantly different from that observed in the transdermal
group (p  0.05) and that in the placebo group (p  0.05).
Subjects using placebo experienced no significant change in
any hormone, lipid, or hemostatic factor values from base-
line to two and four weeks.
Table 1. Baseline Characteristics of Subjects
Variable Placebo Oral CEE
Transdermal
Estradiol
Age (yrs) 60  4 58  7 60  10
Time since menopause (yrs) 11  6 8  9 9  8
Weight (kg) 70  14 68  11 70  10
Body mass index (kg/m2) 28  6 27  5 28  4
Estradiol (pg/ml) 15  9 18  5 16  10
Follicle-stimulating
hormone (mU/ml)
63  18 69  20 63  28
Progesterone (ng/ml) 0.2  0.1 0.3  0.2 0.3  0.1
Luteinizing hormone
(mU/ml)
24  12 24  9 27  17
Total cholesterol (mg/dl) 221  39 229  32 218  34
Triglycerides (mg/dl) 139  54 121  75 134  46
HDL cholesterol (mg/dl) 53  16 61  15 43  8
LDL cholesterol (mg/dl) 140  31 144  29 148  32
Data are presented as the mean value  SD.
CEE  conjugated equine estrogen; HDL  high-density lipoprotein; LDL 
low-density lipoprotein.
Table 2. Effect of Oral CEE or Transdermal Estradiol on Hormones and Lipids After One Month
Variable
Oral CEE Transdermal Estradiol
Before
Treatment
After
Treatment p Value
Before
Treatment
After
Treatment p Value
Estradiol (pg/ml) 18  5 76  28  0.01 16  10 59  66 NS
Follicle-stimulating hormone (ng/ml) 69  20 39  13  0.01 63  28 33  11  0.01
Progesterone (ng/ml) 0.3  0.2 0.2  0.1 NS 0.3  0.1 0.3  0.2 NS
Luteinizing hormone (mU/ml) 24  9 21  11 NS 27  17 20  10 NS
Total cholesterol (mg/dl) 229  32 209  24  0.01 218  34 214  35 NS
Triglycerides (mg/dl) 121  75 144  75  0.05 134  46 120  37 NS
HDL cholesterol (mg/dl) 61  15 65  14  0.01 43  8 43  7 NS
LDL cholesterol (mg/dl) 144  29 115  27  0.01 148  32 147  32 NS
Data are presented as the mean value  SD.
NS  not significant; other abbreviations as in Table 1.
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DISCUSSION
In this study, we report that oral CEE but not transdermal
estradiol therapy for one month significantly increases the
plasma concentration of vWF antigen in postmenopausal
women. Our findings with CEE and vWF in postmeno-
pausal women are intriguing when viewed in the context of
several recent trials such as HERS and ERA, which have
cast doubt on the cardioprotective effect of HRT in post-
menopausal women (16,17). Although we found that treat-
ment for one month with oral CEE decreased PAI-1, t-PA
antigen, total cholesterol, and LDL cholesterol, it signifi-
cantly increased vWF antigen. Oral CEE also increased
HDL cholesterol and triglyceride concentrations. Oral
CEE had no significant effect on fibrin D-dimer or fibrin-
ogen. In contrast, one month of transdermal estradiol
therapy or placebo had no effect on PAI-1, t-PA, fibrin
D-dimer, vWF antigen, fibrinogen, or lipids. The observa-
tion that oral, but not transdermal, administration of estro-
gen alters several markers, including lipoproteins and PAI-1
levels, suggests that the hepatic effects of estrogen regulate
their synthesis and/or clearance (5,10,15), accounting for
the difference in response.
Elevated serum t-PA levels are present in cardiovascular
conditions involving endothelial cell damage (28). Most of
the t-PA in the plasma travels while bound to PAI-1
molecules to form circulating, inactive t-PA/PAI-1 com-
Table 3. Effect of Oral Conjugated Equine Estrogen or Transdermal Estradiol on Hemostatic Factors After One Month
Variable
Oral CEE Transdermal Estradiol
Before
Treatment
After
Treatment % Change p Value*
Before
Treatment
After
Treatment % Change p Value*
PAI-1 (mg/ml) 42  21 36  19 8.2 0.08 34  10 30  12 9.2 0.34
t-PA (mg/ml) 11.2  8.0 9.7  8.1 17.8 0.004 7.8  4.0 9.0  4.0 19.5 0.23
vWF (mU/ml) 835  365 963  372 22.7 0.03 1,151  159 1,025  238 10.5 0.24
Fibrin D-dimer (mU/ml) 339  141 467  354 67.7 0.06 452  116 446  222 4.7 0.72
Fibrinogen (mg/dl) 354  67 368  65 6.9 0.33 363  61 348  45 2.7 0.54
*Relates to the log difference reflecting the percent change. Data are presented as the mean value  SD.
CEE  conjugated equine estrogen; PAI-1  plasminogen activator inhibitor-1; t-PA  tissue-type plasminogen activator; vWF  von Willebrand factor.
Figure 1. The percent change after oral conjugated equine estrogen (CEE) or transdermal estrogen on plasminogen activator inhibitor-1 (PAI-1),
tissue-type plasminogen activator (t-PA), and von Willebrand factor (vWF), compared with baseline. For oral CEE, the test result of the percent change
(p value by analysis of variance [ANOVA]) was p  0.08 for PAI-1, p  0.004 for t-PA, and p  0.03 for vWF. For transdermal estrogen, the test result
of the percent change (p value by ANOVA) was not significant: p  0.34 for PAI-1; p  0.23 for t-PA; and p  0.24 for vWF. Solid bars  PAI-1;
hatched bars  t-PA; and open bars  vWF.
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plexes (29,30). Therefore, oral CEE-induced decreased
t-PA and PAI-1 antigen levels may reflect diminished
t-PA/PAI-1 complexes and, hence, augmented fibrinolytic
activity.
Recent studies have suggested that increased circulating
vWF antigen denotes a poor prognosis in unstable angina
and non–ST-segment elevation myocardial infarction (31).
Moreover, patients undergoing percutaneous coronary in-
terventions who have unstable angina have higher vWF
antigen levels than do patients with stable angina, and the
decrease in vWF antigen after a successful percutaneous
intervention may reflect plaque re-endothelialization and
stabilization (32). Indeed, vWF facilitates platelet aggrega-
tion at sites of vascular injury under high shear stress, and
elevated plasma vWF antigen concentrations correlate with
enhanced platelet adhesion to collagen types I, III, and
IV—all extremely potent physiologic inducers of platelet
aggregation at the site of plaque rupture and vascular injury
(33). Studies with vWF-deficient mice indicate that the
absence of vWF predominantly affects aortic regions with
disturbed flow that are prone to atherosclerosis (34). vWF
may recruit platelets and leukocytes to the lesion in a
flow-dependent fashion or may be part of the mechano-
transduction pathway that regulates the endothelium’s re-
sponse to shear stress (34).
Therefore, the oral CEE-mediated increase of vWF
antigen at one month in our study may partially explain the
results of HERS, which found an early increase in cardio-
vascular events after oral CEE and MPA. It should be noted
that van Baal et al. (35) found a 14% decrease in vWF in 14
healthy postmenopausal subjects after three months of oral
CEE. Cushman et al. (36) found no effect of four different
estrogen/progestin hormone preparations on vWF antigen
levels in 365 patients after 12 months. One study measured
the effect of oral CEE and transdermal estrogen after one
month; however, in that study, vWF was not measured (5).
In a study by Lip et al. (37), 27 premenopausal women
(average age 43.6 years) received CEE, 0.625 mg, following
a hysterectomy and bilateral salpingo-oophorectomy. They
found a decrease in plasma levels of both vWF and t-PA
after six weeks of CEE (37). In contrast to the subjects
described here, no subjects were naturally postmenopausal
for at least one year; all had surgically induced menopause;
all were considerably younger (as expected of a premeno-
pausal population); and all had vasomotor symptoms. Fur-
thermore, the investigators acknowledge that stress and
blood loss, a consequence of surgery versus naturally occur-
ring menopause, might have accounted for the findings.
The opportunity to evaluate the effects of CEE and
transdermal estradiol after one month may provide insight
into the time course of variables affected by estrogen.
Although there are a considerable number of reports docu-
menting estrogen’s effect on markers of fibrinolysis and
hemostasis, the results are not uniform. Tables 4 and 5
summarize the existing, sometimes contradictory, findings
of 20 studies (5,10–13,15,35,36,38–49). From this sum-
mary, we conclude that variability in the findings could be
related to study design: estrogen formulations (e.g., CEE,
estradiol valerate, micronized estradiol, 17-beta-estradiol),
the size of dose, the method of estrogen replacement (e.g.,
cyclical, continuous), monotherapy or combination with
progestin, the age of subjects, the time since the start of
menopause, the duration of treatment, and the time of
sampling. Although there are several reports relating the
effect of ERT and HRT on PAI-1, few measured vWF. No
other study measured vWF at one month, but more likely
measured it at 3 to 4, 6, 12, and 36 months. Two studies
collected samples as early as three months; however, one
used micronized estradiol plus 1 or 2 mg dydrogesterone
(35) and found that vWF decreased, and the other used
CEE plus 5 mg medrogestone (12) and found no effect on
vWF.
Thus, it is possible that oral CEE exerts very early effects,
increasing vWF antigen after one month, which may then
dissipate over time with no effects found on vWF levels by
three months to one year. We found that one month of
transdermal estradiol had no effect on vWF antigen levels, a
finding consistent with the results of a study of transdermal
estradiol in 28 postmenopausal hysterectomized subjects
after four months of therapy (42).
Our finding that oral, but not transdermal, estrogen
increases plasma vWF antigen after one month of therapy is
noteworthy in that vWF is not only a marker of endothelial
dysfunction and enhanced atherothrombotic activity, but
also is a marker of inflammation (36,41). In this regard,
recent reports have discovered that HRT initially increases
levels of C-reactive protein (CRP), an inflammatory marker
that is a potent prognosticator of an increased risk of
cardiovascular events in both women and men (36,37,
42,50). Indeed, HRT appears to increase high-sensitivity
CRP within four to eight months of the initiation of
therapy. Therefore, oral CEE may cause an early increase in
both inflammation and hemostasis, as evidenced by early
elevations in both vWF and CRP, which result in an early
increase in cardiovascular events. Furthermore, our findings
that oral CEE, but not transdermal estradiol, induced the
aforementioned effects is intriguing considering that the
proinflammatory cytokine, interleukin-6, which is the pri-
mary stimulant of hepatic CRP (51), is also a potent inducer
of vWF (52).
Oral CEE increased HDL cholesterol and decreased
LDL cholesterol and total cholesterol, even in subjects who
were overweight (Table 2), which corresponds to previous
studies demonstrating that oral CEE has beneficial effects
on the lipid profile (53,54). However, we also found that
oral CEE concomitantly increases triglycerides, as evi-
denced by previous studies (53,54). In addition, it should be
noted that, despite decreasing total cholesterol and LDL
cholesterol, oral CEE actually decreases the LDL particle
size, increases the very low density lipoprotein size, and only
minimally reduces the concentration of apolipoprotein B
(53,54). Furthermore, our study demonstrates that trans-
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Table 4. Reports Evaluating Hemostatic and Fibrinolytic Markers in Postmenopausal Women After Estrogen
Study (Ref.)
Design; Number of Subjects (n);
and Age (years)
Time of
Sampling Oral Estrogen Transdermal Estrogen
Andersen et al. (38) Active treatment and reference group;
n  60; age 40–60 years
Baseline and 3, 6,
and 12 months
Estradiol valerate, 2 mg/day
(cont or cyc)  CA, 1 mg/day
Not administered
Boschetti et al. (39) Random allocation; n  40 Baseline and 2, 4,
and 12 months
CEE, 0.625 mg (3 one-week
cycles)  MPA, 10 mg/day
(third week)
Transdermal estradiol,
0.05 mg/day (3 one-week
cycles)  MPA, 10 mg/
day (third week)
Chen et al. (40) n  41 Baseline and 3, 6,
and 12 months
Estradiol valerate, 2 mg/day
(cont or cyc)  CA, 1 mg
Estradiol, 1.5 mg  MPA, 5
mg
Cushman et al. (36) PEPI: randomized double-blind,
placebo-controlled; n  383;
mean age 56 years
Baseline and 12
and 36 months
CEE, 0.625 mg; CEE  MPA,
10 mg/day (cyc); CEE 
MPA, 2.5 mg/day (cont);
CEE  MP, 200 mg/day (cyc)
Not administered
Cushman et al. (41) Cardiovascular health study:
population-based, longitudinal;
n  290; mean age 73 years
Annually CEE (92%); CEE  MPA
(cont or cyc)
Not administered
DeMitrio et al. (42) Hysterectomized women; n  28;
age range 44–65 years (mean 47)
Baseline and 4
months
Not administered 17-beta-estradiol, 50 g/24 h
Gilabert et al. (11) n  12 oral, n  12 transdermal Baseline and 3–4
and 12 months
Estradiol valerate, 2 mg/day
 MPA, 2.5 mg/day
Estradiol, 0.5 mg  MPA,
2.5 mg/day
Gottsater et al. (43) Part 1: double-blind, randomized trial
for 3 months; part 2: open study
for 9 months; postmenopausal
women; n  51; age range 53–54
years
Baseline and 3
and 12 months
Estradiol valerate, 2 mg  MPA,
10 mg for 10 days every
3 months
Not administered
Hoibraaten et al. (44) Estrogen in women with
atherosclerosis study: open
randomized trial; n  118;
age 71 years
Baseline and 3
and 12 months
Not administered 17-beta-estradiol, 50 g/24 h
 MPA, 5 mg (cyc)
Koh et al. (5) Randomized, crossover; n  50 (30
oral, 20 transdermal); mean age
for oral 55 years, mean age for
transdermal 56 years
Baseline and
1 month
CEE, 0.625 mg/day or CEE,
0.625 mg/day  MPA, 2.5 mg
Estradiol, 0.1 mg/day or
estradiol, 0.1 mg/day 
MPA, 2.5 mg
Kroon et al. (10) Crossover; n  23; age 65 years Baseline and
6 weeks
CEE, 0.625 mg/day 17-beta-estradiol, 0.05 mg/
day
Lindoff et al. (45) Open, prospective trial with active
treatment vs. control; n  42
treated, n  18 untreated
2 years Not administered 17-beta-estradiol, 50 g/24 h
 MPA, 5 mg (cyc)
Luyer et al. (46) Placebo-controlled; n  26;
age range 55–80 years
Baseline and
3 months
CEE, 0.625 mg/day Not administered
Scarabin et al. (15) Open, randomized trial with control
group; n  45; age 45–64 years
Baseline and
6 months
17-beta-estradiol, 2 mg/day
 MP, 200 mg/day (cyc)
17-beta-estradiol gel,
2.5 mg/day  MP,
200 mg/day (cyc)
Seljeflot et al. (47) Postmenopausal women with
coronary artery disease; n  98;
age range 59–71 years
Baseline and 3
and 12 months
Not administered 17-beta-estradiol, 50 g/day
 sequential MPA, 5 mg
for 14 days every third
month
Shahar et al. (13) ARIC study cohort with case control;
n  59; age 45–64 years
Baseline Estrogen or estrogen progestin
combination; type not specified
Not specified
Teede et al. (48) Double-blind, placebo-controlled;
n  42; age 50–75 years
Baseline and 6
weeks
Estradiol, 2 mg  continuous
norethisterone acetate, 1 mg
Not administered
van Baal et al. (35) Prospective, randomized, open;
n  27; mean age 52 years
Baseline and 3, 12,
and 15 months
Micronized estradiol, 1 mg 
dydrogesterone, 5–10 mg or
micronized estradiol, 2 mg
 dydrogesterone
Not administered
Vehkavaara et al. (49) Randomized, placebo-controlled;
n  27; age 52 years;
mean age 55 years
Baseline and 2
and 12 weeks
Estradiol, 2 mg Estradiol, 50 g/day
Winkler et al. (12) n  42 Baseline and
3 months
CEE, 0.6 mg  medrogestone,
5 mg (cyc)
17-beta-estradiol 50 g/day
ARIC  Atherosclerosis Risk In Communities study; CA  cyprotereone acetate, anti-androgen, progestational compound with androgen receptor blocking capacity; CEE 
conjugated equine estrogen; cont  continuous; cyc  cyclical; MP  micronized progesterone; MPA  medroxyprogesterone acetate; PEPI  Postmenopausal
Estrogen/Progestin Interventions study.
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dermal estradiol has no significant effect on lipids. We
found a positive correlation between the oral CEE-induced
increase in vWF and HDL cholesterol. The mechanism
underlying this interesting observation merits further inves-
tigation.
Study limitations. Of the 48 subjects randomized, 38
(79%) completed the trial and 10 (21%) discontinued
treatment because of adverse events or because they were
deemed no longer eligible or noncompliant. In subjects
taking ERT for the first time, continuance of ERT is
sporadic, and the current subjects parallel this experience. In
the Massachusetts Women’s Health Survey, among patients
taking ERT for the first time, 20% stopped taking the drug
within nine months and 10% used it on an intermittent
basis (55). In a survey from The North American Meno-
pause Society, among 833 women, 8% who had used ERT
or HRT in the past stopped taking it, and among 58% who
had never used it, 14% never tried it, even though it was
prescribed (56). A second limitation is that the number of
subjects assigned to transdermal estradiol and placebo is
relatively small. The rationale for the randomization
scheme, which favored oral administration, was the consid-
eration that the majority of postmenopausal women treated
with hormones use CEE, and furthermore, oral CEE was
used in the HERS and ERA study, as well as the Women’s
Health Initiative. Thus, the findings reported here may
provide insight into the mechanisms of benefit and risk, as
well as the time course of markers, following administration
of CEE in the postmenopausal years.
Conclusions. One month of oral CEE, but not transder-
mal estradiol, significantly increases the plasma levels of
vWF antigen. Taken together, these data suggest that oral
CEE may have very early deleterious effects promoting
atherothrombosis by increasing a hemostatic factor, which
encompasses the interaction of endothelial dysfunction,
platelet aggregation, and inflammation.
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